Arizona State Retirement System Buys 373 Shares of RxSight, Inc. (NASDAQ:RXST)

Arizona State Retirement System grew its stake in shares of RxSight, Inc. (NASDAQ:RXST) by 5.0% during the second quarter, Holdings Channel reports. The institutional investor owned 7,765 shares of the company’s stock after purchasing an additional 373 shares during the quarter. Arizona State Retirement System’s holdings in RxSight were worth $467,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. CWM LLC lifted its holdings in RxSight by 727.5% in the second quarter. CWM LLC now owns 422 shares of the company’s stock worth $25,000 after buying an additional 371 shares during the period. Larson Financial Group LLC purchased a new position in shares of RxSight during the first quarter valued at approximately $51,000. RiverPark Advisors LLC lifted its holdings in shares of RxSight by 361.4% during the first quarter. RiverPark Advisors LLC now owns 3,082 shares of the company’s stock valued at $159,000 after purchasing an additional 2,414 shares during the last quarter. Amalgamated Bank lifted its holdings in shares of RxSight by 7.7% during the fourth quarter. Amalgamated Bank now owns 4,148 shares of the company’s stock valued at $167,000 after purchasing an additional 298 shares during the last quarter. Finally, Clear Rock Advisors LLC purchased a new position in shares of RxSight during the fourth quarter valued at approximately $172,000. 78.78% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the stock. Wells Fargo & Company reduced their price target on shares of RxSight from $68.00 to $54.00 and set an “overweight” rating for the company in a research report on Tuesday, August 6th. Needham & Company LLC reissued a “buy” rating and set a $66.00 price target on shares of RxSight in a research report on Friday. BTIG Research raised their price target on shares of RxSight from $72.00 to $73.00 and gave the company a “buy” rating in a research report on Monday, July 15th. Stifel Nicolaus reduced their price target on shares of RxSight from $70.00 to $65.00 and set a “buy” rating for the company in a research report on Tuesday, August 6th. Finally, Oppenheimer reduced their price target on shares of RxSight from $72.00 to $65.00 and set an “outperform” rating for the company in a research report on Tuesday, August 6th. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $60.14.

Insider Transactions at RxSight

In other news, insider Ilya Goldshleger sold 9,000 shares of the firm’s stock in a transaction that occurred on Monday, August 5th. The shares were sold at an average price of $39.25, for a total transaction of $353,250.00. Following the transaction, the insider now directly owns 42,246 shares of the company’s stock, valued at $1,658,155.50. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other RxSight news, CFO Shelley B. Thunen sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $58.61, for a total value of $586,100.00. Following the completion of the sale, the chief financial officer now directly owns 13,938 shares in the company, valued at $816,906.18. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Ilya Goldshleger sold 9,000 shares of the firm’s stock in a transaction that occurred on Monday, August 5th. The shares were sold at an average price of $39.25, for a total transaction of $353,250.00. Following the completion of the sale, the insider now owns 42,246 shares of the company’s stock, valued at $1,658,155.50. The disclosure for this sale can be found here. Corporate insiders own 9.36% of the company’s stock.

RxSight Stock Performance

Shares of NASDAQ:RXST opened at $55.54 on Tuesday. The firm has a market cap of $2.05 billion, a PE ratio of -44.08 and a beta of 1.22. The firm’s 50 day simple moving average is $50.75 and its 200-day simple moving average is $53.97. RxSight, Inc. has a one year low of $20.66 and a one year high of $66.54.

RxSight (NASDAQ:RXST) last issued its earnings results on Monday, August 5th. The company reported ($0.16) EPS for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.06. The business had revenue of $34.89 million for the quarter, compared to analyst estimates of $32.33 million. RxSight had a negative net margin of 31.92% and a negative return on equity of 19.33%. The company’s quarterly revenue was up 67.6% compared to the same quarter last year. During the same period last year, the company posted ($0.40) earnings per share. Equities research analysts predict that RxSight, Inc. will post -0.81 EPS for the current fiscal year.

RxSight Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.